top of page
About
Home
Team
Partnerships
Send us your innovation
Contact
EN
JP
We are an asset-light, emerging commercial-stage biopharma and MedTech operating company that in-licenses early, de-risked assets to commercialize in Japan and the APAC region
News & Updates
HekaBioとAlpha Tau Medical、固形腫瘍治療機器「Alpha DaRT システム」が日本で製造販売承認を取得
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
Expanding Generational Health Access in Japan: A Strategic Collaboration Oct 2, 2025
Indonesia Inovasi Sehat and HekaBio Sign Strategic Agreement to Advance Healthcare Innovation in Indonesia Oct 1, 2025
NKGen and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan July 21, 2025
HekaBio Enters Strategic Partnership with Alfresa Holdings Corporation June 16, 2025
HekaBio Welcomes Deron Wolfe as Chief Financial Officer June 10, 2025
Rodney Kelly Joins HekaBio as Chief Growth Officer April 1, 2025
Dr. Yoshimura at the Institute of Science Tokyo has published "Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy." Feb. 26
1
2
3
4
bottom of page
